Truvada®: Clinical Trials

26 completed, 5 active not recruiting, 1 recruiting, 1 terminated. 16 Phase 3, 10 Phase 2, 3 Phase 4, 2 Phase 1, 1 Early Phase 1.

By phase and status

Phase	Trials	Status
Phase 3	16	Completed 13, Active not recruiting 2, Terminated 1
Phase 2	10	Completed 7, Active not recruiting 3
Phase 4	3	Completed 2, Unknown 1
Phase 1	2	Completed 2
Early Phase 1	1	Completed 1
Not applicable	1	Withdrawn 1

Follow Truvada®: new trials by email Literature Review of Truvada® trials Research Report on Truvada®

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Implementation Study of Lenacapavir Pre-exposure Prophylaxis for HIV Prevention Lenacapavir Injection, Emtricitabine/tenofovir disoproxil fumarate (F/TDF), Emtricitabine/tenofovir alafenamide (F/TAF) - HIV Infections		Recruiting	Gilead Sciences	3000	2026-03-17	2026-10-21
Study of Lenacapavir Taken Twice a Year for HIV Pre-Exposure Prophylaxis (PrEP) Lenacapavir Injection, Lenacapavir Tablet, Emtricitabine/tenofovir disoproxil fumarate (F/TDF) - Pre-Exposure Prophylaxis of HIV Infection	Phase 2	Active not recruiting	Gilead Sciences	268	2024-10-07	2026-06-15
Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) for Prevention of HIV in People Who Inject Drugs (HPTN 103) Lenacapavir Injection, Lenacapavir Tablet, Emtricitabine/tenofovir disoproxil fumarate (F/TDF) - Pre-Exposure Prophylaxis of HIV Infection	Phase 2	Active not recruiting	Gilead Sciences	181	2023-12-13	2026-08-13
Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) in Prevention of HIV in Cisgender Women in the United States (HPTN 102) Lenacapavir Tablet, Lenacapavir Injection, Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) - Pre-Exposure Prophylaxis of HIV Infection	Phase 2	Active not recruiting	Gilead Sciences	253	2023-11-17	2026-08-17
Pre-Exposure Prophylaxis Study of Lenacapavir and Emtricitabine/Tenofovir Alafenamide in Adolescent Girls and Young Women at Risk of HIV Infection Oral Lenacapavir (LEN), Subcutaneous (SC) Lenacapavir (LEN), F/TAF - Pre-Exposure Prophylaxis of HIV Infection	Phase 3	Active not recruiting	Gilead Sciences	5368	2021-08-30	2026-10-16
Pre-Exposure Prophylaxis Study of Lenacapavir in Cisgender Men, Transgender Women, Transgender Men, and Gender Nonbinary People at Risk for HIV Infection Oral Lenacapavir (LEN), F/TDF, Sub-cutaneous (SC) Lenacapavir (LEN) - Pre-Exposure Prophylaxis of HIV Infection	Phase 3	Active not recruiting	Gilead Sciences	3292	2021-06-28	2026-10-06
Comparative Study of PK and BE of VM-1500FDC (Fixed-dose Combination) and Elpida® With Truvada® сo-administrated 1 Daily Fasting in Healthy Subjects VM-1500FDC, Elpida®, Truvada® - HIV-1-infection	Phase 1	Completed	Viriom	140	2018-06-01	2018-10-30
Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment Naive, HIV-1 and Hepatitis B Co-Infected Adults B/F/TAF, Placebo to match DTG, Placebo to match F/TDF - HIV-1/HBV Co-Infection	Phase 3	Completed	Gilead Sciences	244	2018-05-30	2025-03-19
Pharmacokinetics and Pharmacodynamics of DMPA With HIV PrEP tenofovir/emtricitabine, DMPA - HIV/AIDS, Contraception	Early Phase 1	Completed	Sharon Achilles	15	2017-11-17	2020-12-03
HIV PrEP Priming of Immune Effectors TDF/FTC - HIV-1 Infections	Phase 4	Unknown	MRC/UVRI and LSHTM Uganda Research Unit	220	2017-05-25	2017-09-19
Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex With Men and Are At Risk of HIV-1 Infection F/TAF, F/TDF, F/TAF Placebo - Pre-Exposure Prophylaxis of HIV-1 Infection	Phase 3	Terminated	Gilead Sciences	5399	2016-09-02	2026-09-08
Safety and Efficacy of Switching to a FDC of B/F/TAF From E/C/F/TAF, E/C/F/TDF, or ATV+RTV+FTC/TDF in Virologically Suppressed HIV-1 Infected Women E/C/F/TAF, E/C/F/TDF, ATV - HIV-1 Infection	Phase 3	Completed	Gilead Sciences	472	2016-02-19	2020-03-04
Switching From a Tenofovir Disoproxil Fumarate (TDF) Containing Regimen to Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Infected Adults Aged ≥ 60 Years E/C/F/TAF, TDF, FTC - HIV-1 Infection	Phase 3	Completed	Gilead Sciences	167	2015-12-22	2020-03-04
Study to Evaluate the Safety and Efficacy of Switching From Regimens Consisting of Boosted Atazanavir or Darunavir Plus Either Emtricitabine/Tenofovir or Abacavir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV-1 Infected Adults RTV, ATV, DRV - HIV-1 Infection	Phase 3	Completed	Gilead Sciences	578	2015-11-20	2020-12-29
Renal Effect of Stribild or Other Tenofovir DF-containing Regimens Compared to Ritonavir-boosted Atazanavir Plus Abacavir/Lamivudine in Antiretroviral Treatment-naive HIV-1 Infected Adults STB, TVD, ATR - HIV-1 Infection	Phase 4	Completed	Gilead Sciences	72	2014-12-15	2018-01-03
Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy triple therapy, dual therapy - HIV	Phase 3	Completed	University Hospital, Tours	224	2014-12-01	2025-12-26
PRe-Exposure Prophylaxis Acceptability & Readiness Assessments for Toronto gaY, Bisexual and Other Men Who Have Sex With Men-5 Tenofovir/emtricitabine - HIV, Human Immunodeficiency Virus	Phase 4	Completed	Unity Health Toronto	52	2014-10-01	2016-10-17
Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF FTC/TDF, F/TAF, Allowed third antiretroviral agent - HIV-1 Infection	Phase 3	Completed	Gilead Sciences	668	2014-05-06	2020-03-12
SCOPE: Strategies to Combine PrEP With Prevention Efforts Once daily Truvada® - HIV	Not applicable	Withdrawn	FHI 360		2013-06-01	2013-07-15
Factors Affecting PrEP Adherence Emtricitabine/tenofovir disoproxil - HIV Infection		Completed	University of North Carolina, Chapel Hill	167	2013-06-01	2017-02-28

Showing 20 of 35. Sign in to see all of them.

Conditions studied

HIV Infections (11)  ·  Acquired Immunodeficiency Syndrome (5)  ·  Hepatitis B, Chronic (4)  ·  Hepatitis B (3)  ·  Hepatitis C (1)

Sponsors

Gilead Sciences (23)  ·  University of North Carolina, Chapel Hill (4)  ·  FHI 360 (1)  ·  Groupe d'Etude sur le Risque d'Exposition des Soignants aux Agents Infectieux (1)  ·  MRC/UVRI and LSHTM Uganda Research Unit (1)  ·  Merck Sharp & Dohme LLC (1)  ·  Sharon Achilles (1)  ·  Unity Health Toronto (1)  ·  University Hospital, Tours (1)  ·  Viriom (1)

Countries

United States (23)  ·  France (14)  ·  United Kingdom (11)  ·  Puerto Rico (10)  ·  Spain (10)  ·  Canada (9)  ·  Italy (9)  ·  Belgium (7)  ·  Germany (7)  ·  Dominican Republic (6)  ·  Thailand (6)  ·  Australia (5)  ·  Netherlands (5)  ·  Austria (4)  ·  Greece (4)

Top investigators

Sybil Hosek, PhD (2)  ·  Amy Corneli, Ph.D. (1)  ·  Anuj Gaggar, MD/PhD (1)  ·  Darrell Tan, MD FRCPC PhD (1)  ·  Elena Mazygula, PhD (1)  ·  Huyen Cao, MD (1)  ·  Jennifer Deese, MPH (1)

Results publications

PMID 19052126, PMID 20955704, PMID 23234725, PMID 23364953, PMID 23939953, PMID 25179493, PMID 25277773, PMID 25532501, PMID 25788199, PMID 25987775, PMID 27658343, PMID 28215615, PMID 30795958, PMID 31136052, PMID 31179503, PMID 36912172, PMID 21811136, PMID 23532097, PMID 24368224, PMID 24861361, PMID 24929235, PMID 25046847, PMID 25622055, PMID 26181707, PMID 26538525, PMID 27036991, PMID 27534671, PMID 27545497, PMID 27562742, PMID 27572401, PMID 27774892, PMID 28013265, PMID 28259777, PMID 28873128, PMID 29368537, PMID 29486737, PMID 29925490, PMID 30260797, PMID 30280906, PMID 30530721, PMID 30932951, PMID 31121013, PMID 31303140, PMID 31350995, PMID 31355775, PMID 31430369, PMID 31578954, PMID 31609930, PMID 31826005, PMID 32711800

NIH funding

2023 (3), 2004 (2), 2015 (2), 2009 (1), 2014 (1), 2016 (1), 2018 (1)